1. Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia
- Author
-
Jones P, Siena G, Hameed BMZ, and Somani BK
- Subjects
rezum ,bph ,prostate ,benign prostatic hyperplasia ,minimally invasive surgery ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Patrick Jones,1,2 Giampaolo Siena,3 BM Zeeshan Hameed,2,4 Bhaskar K Somani2,5 1Department of Urology, Haukeland University Hospital, Bergen, Norway; 2EAU Young Academic Urology Urolithiasis and Endourology Working Party, Arnhem, Netherlands; 3Department of Urology, Careggi University Hospital, Florence, Italy; 4Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India; 5Department of Urology, University Hospital Southampton, Southampton, UKCorrespondence: Patrick JonesDepartment of Urology, Haukeland University Hospital, Bergen, NorwayTel/Fax +447950050667Email patrick.jones1@nhs.netAbstract: Benign prostate disease is a disease of prevalence and over 25% of men affected by bothersome lower urinary tract symptoms (LUTS) as a result of it will require surgical intervention during their lifetime. While transurethral resection of the prostate (TURP) has served as the cornerstone treatment for many years, there now exist a multitude of minimally invasive alternatives including the Rezum system. The latter is a novel form of transurethral water vapour therapy, which is attracting increasing attention. It utilizes convective water vapour energy (WAVE) and thereby radiofrequency (RF) in order to generate heat energy. Early studies have demonstrated promising results. To date there have been 12 studies published on Rezum, however only one randomized trial. This review offers an overview and evaluation of this emerging evidence.Keywords: Rezum, BPH, prostate, benign prostatic hyperplasia, minimally invasive surgery
- Published
- 2021